Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)

Biochemical Pharmacology

Volumn 61, Issue 12, 2001, Pages 1497-1507

  Azuma, Atsushi ^a   Huang, Peng ^a   Matsuda, Akira ^b   Plunkett, Williamm ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

CNDAC; DNA polymerase; DNA synthesis; Nucleoside analog

Indexed keywords

2' C CYANO 2' DEOXY 1 BETA DEXTRO ARABINO PENTOFURANOSYLCYTOSINE; 2' C CYANO 2' DEOXY 1 BETA DEXTRO ARABINO PENTOFURANOSYLCYTOSINE 5' DIPHOSPHATE; 2' C CYANO 2' DEOXY 1 BETA DEXTRO ARABINO PENTOFURANOSYLCYTOSINE 5' MONOPHOSPHATE; 2' C CYANO 2' DEOXY 1 BETA DEXTRO ARABINO PENTOFURANOSYLCYTOSINE 5' TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYTIDINE DERIVATIVE; CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE DERIVATIVE; DNA; DNA DIRECTED DNA POLYMERASE ALPHA; GUANOSINE PHOSPHATE; NUCLEOTIDE; PRIMER DNA; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DNA TEMPLATE; DRUG ACCUMULATION; DRUG COMPETITION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG RETENTION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; LYMPHOID CELL; POLYMERIZATION; PRIORITY JOURNAL;

EID: 0035876975     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00617-7     Document Type: Article

References (42)

1. Keating M.J., McCredie K.B., Bodey G.P., Smith T.L., Gehan E., Freireich E.J. Improved prospects for long-term survival in adults with acute myelogenous leukemia. J Am Med Assoc. 248:1982;2481-2486.
2. Ghaddar H.M., Plunkett W., Kantarjian H.M., Pierce S., Freireich E.J., Keating M.J., Estey E.H. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 8:1994;1269-1274.
3. Cassileth P.A., Harrington D.P., Appelbaum F.R., Lazarus H.M., Rowe J.M., Paietta E., Willman C., Hurd D.D., Bennett J.M., Blume K.G., Head D.R., Wiernik P.H. Chemotherapy compared with autologous or allo geneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 339:1998;1649-1656.
4. Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine preclinical pharmacology and mechanisms of action . Semin Oncol. 23:(Suppl 10):1996;3-15.
5. Kaye S.B. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 78:(Suppl 3):1998;1-7.
6. Noble S., Goa K.L. Gemcitabine a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer . Drugs. 54:1997;447-472.
7. Grunewald R., Kantarjian H., Du M., Faucher K., Tarassoff P., Plunkett W. Gemcitabine in leukemia a phase I clinical, plasma, and cellular pharmacology study . J Clin Oncol. 10:1992;406-413.
8. Zinzani P.L., Baliva G., Magagnoli M., Bendandi M., Madugno G., Gherlinzoni F., Orcioni G.F., Ascani S., Simoni R., Pileri S.A., Tura S. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma experience in 44 patients . J Clin Oncol. 18:2000;2603-2606.
9. Santoro A., Bredenfeld H., Devizzi L., Tesch H., Bonfante V., Viviani S., Fieldler F., Parra H.S., Benoehr C., Pacini M., Bonnadonna G., Diehl V. Gemcitabine in the treatment of refractory Hodgkin's disease results of a multicenter phase II study . J Clin Oncol. 18:2000;2615-2619.
10. Furth J.J., Cohen S.S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5′-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res. 28:1968;2061-2067.
11. Chou T.-C., Arlin Z., Clarkson B.D., Philips F.S. Metabolism of 1-β-D-arabinofuranosylcytosine in human leukemia cells. Cancer Res. 37:1977;3561-3570.
12. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031.
13. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
14. Kufe D.W., Major P.P., Egan E.M., Beardsley J.P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem. 225:1980;8997-9000.
15. Townsend A.J., Cheng Y.-C. Sequence specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro visualization of chain elongation on a defined template . Mol Pharmacol. 32:1987;330-339.
16. Graham F.L., Whitmore G.F. Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5′-triphosphate. Cancer Res. 30:1970;2636-2644.
17. Searcy C., Huang P., Gandhi V., Plunkett W. DNA sequence plays a role in the effects of gemcitabine on strand elongation with DNA polymerase α Proc Am Assoc Cancer Res. 36:1995;404.
18. Mikita T., Beardsley G.P. Functional consequences of the arabinosylcytosine structural lesion in DNA. Biochemistry. 27:1988;4698-4705.
19. Moore E.C., Cohen S.S. Effects of arabinonucleotides on ribonucleotide reduction by an enzyme system from rat tumor. J Biol Chem. 242:1967;2116-2118.
20. Heinemann V., Xu Y.-Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 38:1990;567-572.
21. Baker C.H., Banzon J., Bollinger J.M., Stubbe J., Samano V., Robins M.J., Lippert B., Jarvi E., Resvick R. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates potent mechanism-based inhibitors of ribonucleotide reductase . J Med Chem. 34:1991;1879-1884.
22. Gandhi V., Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 50:1990;3675-3680.
23. Shewach D.S., Hahn T.M., Chang E., Hertel L.W., Lawrence T.S. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54:1994;3218-3223.
24. Matsuda A., Nakajima Y., Azuma A., Tanaka M., Sasaki T. Nucleosides and nucleotides. 100. 2′-C-Cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine (CNDAC) design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside . J Med Chem. 34:1991;2917-2919.
25. Azuma A., Nakajima Y., Nishizono N., Minakawa N., Suzuki M., Hanaoka K., Kobayashi T., Tanaka M., Sasaki T., Matsuda A. Nucleosides and nucleotides. 122. 2′-C-Cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J Med Chem. 36:1993;4183-4819.
26. Matsuda A., Azuma A. 2′-C-Cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine (CNDAC) a mechanism-based DNA-strand-breaking antitumor nucleoside . Nucleosides Nucleotides. 14:1995;461-471.
27. 4-palmitoyl derivative (CS-682). Int J Cancer. 82:1999;226-236.
28. Tanaka M., Matsuda A., Terao T., Sasaki T. Antitumor activity of a novel nucleoside, 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors. Cancer Lett. 64:1992;67-74.
29. Matsuda A., Azuma A., Nakajima Y., Takenuki K., Dan A., Iino T., Yoshimura Y., Minakawa N., Tanaka M., Sasaki T. Design of new types of antitumor nucleosides the synthesis and antitumor activity of 2′-deoxy-(2′-C-substituted) cytidines . Chu C.K., Baker D.C. Nucleosides and nucleotides as antitumor and antiviral agents. 1993;1-22 Plenum Publishing, New York.
30. Donehower R.C., Dees E.C., Baker S.D., Summerson L., Carducci M.A., Izumi T., Kobayashi T. A phase I study of CS-682, an oral antimetabolite, in patients with refractory solid tumors. Proc Am Soc Clin Oncol. 19:2000;196a.
31. Simon E.S., Grabowski S., Whitesides G.M. Convenient synthesis of cytidine 5′-triphosphate, guanosine 5′-triphosphate, and uridine 5′-triphosphate and their use in the preparation of UDP-glucose, UDP-glucuronic acid, and GDP-mannose. J Org Chem. 55:1990;1834-1841.
32. Huang P., Chubb S., Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine a mechanism for cytotoxicity . J Biol Chem. 265:1990;16617-16625.
33. Carmichael J., Degraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay; assessment of chemosensitivity testing. Cancer Res. 47:1987;943-946.
34. Boosalis M.S., Petruska J., Goodman M.F. DNA polymerase insertion fidelity. Gel assay for site-specific kinetics. J Biol Chem. 262:1987;14689-14696.
35. Parker W.B., White E.L., Shaddix S.C., Ross L.J., Buckheit R.W., Germany J.M., Secrist J.A., Vince R., Shannon W. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerase α, β, and γ by the 5′-triphosphates of carbovir, 3′-azide-3′-deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine. J Biol Chem. 266:1991;1754-1762.
36. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships the combined effects of multiple drugs or enzyme inhibitors . Adv Enzyme Regul. 22:1984;27-55.
37. van der Donk W.A., Yu G., Perez L., Sanchez R.J., Stubbe J., Samano V., Robins M.J. Detection of a new substrate-derived radical during inactivation of ribonucleotide reductase from Escherichia coli by gemcitabine 5′-diphosphate. Biochemistry. 37:1998;6419-6426.
38. Graham F.L., Whitmore G.F. The effect of 1-β-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res. 11:1970;2627-2635.
39. Major P.P., Egan E.M., Herrick J.J., Kufe D.W. Effect of ara-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem Pharmacol. 31:1982;2937-2940.
40. Huang P., Plunkett W. Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol. 39:1991;449-455.
41. Tabata S., Tanaka M., Endo Y., Obata T., Matsuda A., Sasaki T. Antitumor mechanisms of 3′-ethynylcytidine and 3′-ethynyluridine as RNA synthesis inhibitors development and characterization of 3′-ethynyluridine-resistant cells . Cancer Lett. 116:1997;225-231.
42. Huang P., Sandoval A., Van Den Neste E., Keating M.J., Plunkett W. Inhibition of RNA transcription a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine . Leukemia. 14:2000;1405-1413.